ArticleFrontiers in public health2025

The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy.

Vieri Lastrucci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.